Intellia Therapeutics and CRISPR Therapeutics announce U.S. patent
Intellia Therapeutics and CRISPR Therapeutics, two leading genome editing companies focused on the development of potentially curative therapies, announced that the USPTO is expected to issue a CRISPR/Cas9 genome editing patent to Vilnius University. April 26, 2017